169P - Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Cytotoxic agents
Non-small-cell lung cancer
Therapy
Biological therapy
Presenter Petra Neumair
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors P. Neumair1, L. Joos2, R. Warschkow3, S. Ess4, F. Hitz5, M. Frueh5, M.H. Brutsche6, F. Baty6, S. Krähenbühl7, M. Jörger5
  • 1Klinik Für Allgemeine Innere Medizin/hausarztmedizin, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 2Medizinische Universität Basel, Universitätsspital Basel, 4056 - Basel/CH
  • 3Klinik Für Allgemein-, Viszeral-, Endokrin- Und Transplantationschirurgie, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 4Krebsregister St. Gallen-appenzell, Krebsliga Ostschweiz, 9007 St. Gallen - St. Gallen/CH
  • 5Klinik Für Onkologie/hämatologie, Kantonsspital St. Gallen, 9007 St. Gallen - St. Gallen/CH
  • 6Klinik Für Pneumologie/schlafmedizin, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 7Klinische Pharmakologie Und Toxikologie, Universitätsspital Basel, 4031 Basel - Basel/CH

Abstract

Background

Erlotinib is approved for patients with pretreated advanced NSCLC based on a 2-months overall survival (OS) improvement against placebo. Recently, 2 out of 3 prospective clinical studies showed a statistical trend for superior survival in patients with pretreated advanced NSCLC receiving chemotherapy versus erlotinib.

Methods

We collected data of all patients with advanced NSCLC since the approval of erlotinib in 2005. Data included systemic treatment, prognostic covariates such as age, gender, presence of CNS metastases, smoking status, ECOG performance status, radiological response and survival. Primary study endpoint was OS, secondary study endpoint progression-free survival (PFS). We used Kaplan–Meier statistics, multivariate Cox regression and propensity score matching. The study had a power of 87% to detect a survival superiority of 30%.

Results

From 827 patients, we excluded 171 patients for potential curative treatment, 189 for treatment outside our hospital, 204 for

Conclusions

We found chemotherapy not to be superior to erlotinib in pretreated patients with advanced NSCLC.

Clinical trial identification

Internal protocol number EKSG 14/157

Legal entity responsible for the study

Markus Joerger, MD-PhD ClinPharm

Funding

Cantonal Hospital St.Gallen, Switzerland

Disclosure

All authors have declared no conflicts of interest.